CorMedix reported strong Q2 results, exceeding analyst estimates for both adjusted earnings and revenue, primarily driven by robust DefenCath sales. The company also reaffirmed its 2026 sales guidance and increased its adjusted EBITDA guidance, signaling continued positive momentum.
CorMedix Inc. announced impressive second-quarter results, with adjusted earnings and revenue surpassing consensus estimates. The significant driver of this performance was the strong sales of DefenCath, particularly due to the onboarding of a large dialysis organization. This positive financial performance is further bolstered by the company reaffirming its fiscal 2026 sales guidance and raising its adjusted EBITDA guidance, indicating confidence in future growth. For traders, this represents a short-term positive catalyst, as evidenced by the premarket stock jump. Long-term implications are also positive, given the continued expansion plans for REZZAYO and the reaffirmed guidance, suggesting sustained growth potential. The key opportunity lies in the continued successful commercialization of DefenCath and the potential expansion of REZZAYO's indication.